A Clinical Study to Assess the Efficacy and Safety of DA-3002

Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome

A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin®.

Inclusion Criteria:

• Diagnosed with Turner's Syndrome through chromosome analysis
• The chronological age: 2≤AGE≤12
• The yearly growth rate should be less than 6cm; the bone age should be equal or less than 12; the height ≤ 10th percentile for the heights of their agemates
• Before the adolescence, Tuner stage I (breast)
• Normal thyroid function

Exclusion Criteria:

• Growth hormone was administered for 12 months or longer in the past
• Treated with estrogen or adrenal androgens for 12 months or longer in the past
• Malignancy, CNS Trauma, Psychiatric Disorder